title: Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients.
abstract: A transdermal therapeutic system (TTS) is recommended for use in chronic cancer pain, particularly in the advanced stages. The aim of this trial was to study intra- and interindividual variabilities in fentanyl transdermal absorption and investigate physiological and clinical parameters that can influence the absorption in patients treated using a TTS for moderate to severe cancer pain. The study group consisted of 108 patients (71 men and 37 women; mean age, 61.3 years) with chronic cancer pain. A total of 507 patches were analysed. The TTSs used to administer fentanyl were removed after a 72-h period. The amount of fentanyl remaining in the patches was determined using a high-performance liquid chromatography method with ultraviolet detection. Depending on the analgesic requirements of the patient, the dose of fentanyl administered by TTS ranged from 25 to 500 microg/h. The study period was 6 months. Large interindividual variability in the amount of remaining fentanyl in the patches occurred. For 58.1% of patches, absorption was 60 to 84%; for 33.2% of them, it was lower; and for 8.8%, it was higher than this range. The intra-individual variability ranged from 2.8 to 75.1%. The bioavailability of fentanyl was statistically different according to patient age. Patients >75 years of age absorbed 50% of the fentanyl during the selected 72-h period, whereas patients <65 years absorbed 66%. Moreover, there is a significant difference in the percentage of absorbed fentanyl according to the type of cancer. The absorption was higher in patients with breast or digestive cancer than in those with lung cancer. Hyperhidrosis, hypertrichosis and the localization of patches on the skin did not influence bioavailability. For the entire group, transdermal fentanyl treatment provided good to excellent pain relief in the majority of patients.
authors.affiliation: Oncopharmacology Laboratory, Val d'Aurelle Anticancer Centre, Parc Euromédecine, Montpellier, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Solassol
authors.forename: Laetitia
authors.initials: L
authors.lastname: Caumette
authors.forename: Françoise
authors.initials: F
authors.lastname: Bressolle
authors.forename: Frédéric
authors.initials: F
authors.lastname: Garcia
authors.forename: Simon
authors.initials: S
authors.lastname: Thézenas
authors.forename: Cécile
authors.initials: C
authors.lastname: Astre
authors.forename: Stéphane
authors.initials: S
authors.lastname: Culine
authors.forename: Rémi
authors.initials: R
authors.lastname: Coulouma
authors.forename: Frédéric
authors.initials: F
authors.lastname: Pinguet
mesh_terms: D000279:Administration, Cutaneous; D000368:Aged; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D016503:Drug Delivery Systems; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy* / Q000628:therapy; D010146:Pain / Q000188:drug therapy*; D010166:Palliative Care / Q000379:methods*; D015203:Reproducibility of Results; D013997:Time Factors
chemical_list: D000701:Analgesics, Opioid; D005283:Fentanyl